IPO

Brompton Energy Split Corp. unveils a new share offering with a stunning 15.1% yield, but investors must weigh the high rewards against sector volatility.

As crypto crime surges, Blockaid launches a new suite to stop illicit funds in milliseconds, shifting institutional defense from forensics to real-time intervention.

Cybersecurity firm iCOUNTER adds a CMO and CFO with track records of building market leaders and securing major exits, signaling aggressive expansion.

Amid federal policy changes threatening to cut off millions, Yale New Haven Health partners with Escher Health to use AI for enrolling vulnerable patients.

Record profits from gold giants are breathing new life into once-dormant assets, but a closer look reveals a world of opportunity fraught with speculation.

The luggage giant reports a 4.1% revenue increase and a major cash flow turnaround, while advancing plans for a strategic US stock market debut this year.

From malaria vaccines to maglev trains, 12 finalists are celebrated for breakthroughs tackling the world's most pressing environmental and health crises.

McDonald's enters the stadium naming game with a massive community pledge for Chicago, but not all residents are cheering for the new riverfront project.

A new fund, JURY, targets income investors by excluding firms linked to war crimes while donating a portion of its fees to humanitarian causes.

The new CROSSx Disclosed platform combines Wall Street-style trading relationships with blazing speed, aiming to lower costs and risks for institutions.

Packaging giant Huhtamäki repurchases its sustainability-linked bonds at a premium, signaling financial savvy and strong investor confidence.

Arco Vara sells a 25% stake in its Botanica Lozen project, handing management to a local partner to tap into Sofia's booming real estate market.

The nation's largest EMS provider, GMR Solutions, saw its stock surge on its NYSE debut after a major IPO price cut to appease wary investors.

A new study reveals Efsubaglutide Alfa not only controls diabetes but may also improve the body's own insulin-producing cells, heralding a new era.

The utility giant is using a complex forward sale to fund massive infrastructure upgrades, balancing immediate market jitters with long-term strategic growth.

Grupo Nutresa posted a 42% EBITDA surge, but a strong peso and rising financial costs pushed its reported net income into the red. What's behind the numbers?

With a new CEO, a half-billion-dollar war chest, and a novel drug pipeline, Damora Therapeutics is making an aggressive play to redefine blood cancer treatment.

With a novel drug for schizophrenia and deep financial backing, LB Pharmaceuticals is advancing a promising new therapy for complex mental illnesses.

Andersen Group reports a 15.7% revenue jump, but IPO-related costs mask strong operational performance as the firm pursues aggressive global expansion.

Resideo posted strong Q1 results with an 8% revenue jump to $1.91B, setting a positive stage for the planned separation of its ADI distribution arm.